The Cambrian Biopharma-backed cancer treatment developer floated above its range in an offering on the Nasdaq Global Market.

US-based oncology treatment developer Sensei Biotherapeutics has raised $133m in an upsized initial public offering (IPO) on the Nasdaq Global Market that provided an exit for medical research group Cambrian Biopharma. The company issued 7 million shares priced at $19 each, above the $16 to $18 range it had set for the offering, valuing it…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.